Akero Therapeutics, Inc.
General ticker "AKRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
Akero Therapeutics, Inc. follows the US Stock Market performance with the rate: 30.9%.
Estimated limits based on current volatility of 0.1%: low 54.47$, high 54.62$
Factors to consider:
- Total employees count: 63 (+12.5%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Strategic risks and growth management, Acquisition/divestiture risks, Regulatory and compliance, Limited operating history
- Current price 24.4% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [16.52$, 43.91$]
- 2025-12-31 to 2026-12-31 estimated range: [13.04$, 36.23$]
Financial Metrics affecting the AKRO estimates:
- Negative: with PPE of -7.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.04 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 90.83 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.24 <= 0.79
Short-term AKRO quotes
Long-term AKRO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $115.16MM | $172.87MM | $285.42MM |
| Operating Income | $-115.16MM | $-172.87MM | $-285.42MM |
| Non-Operating Income | $3.12MM | $21.11MM | $33.36MM |
| Interest Expense | $0.74MM | $3.10MM | $4.67MM |
| R&D Expense | $85.28MM | $141.80MM | $247.50MM |
| Income(Loss) | $-112.03MM | $-151.76MM | $-252.06MM |
| Profit(Loss)* | $-112.03MM | $-151.76MM | $-252.06MM |
| Stockholders Equity | $326.56MM | $535.31MM | $750.11MM |
| Assets | $356.57MM | $580.27MM | $825.89MM |
| Operating Cash Flow | $-92.52MM | $-145.37MM | $-230.11MM |
| Capital expenditure | $0.00MM | $0.00MM | $1.00MM |
| Investing Cash Flow | $-63.83MM | $-223.62MM | $-109.71MM |
| Financing Cash Flow | $255.63MM | $353.32MM | $445.85MM |
| Earnings Per Share** | $-2.87 | $-2.89 | $-3.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.